Marksans Pharma
Pharmaceuticals
Acquired Nova Pharmaceuticals in 2005.

Overall

Owned IND
Rating D+
About the Ratings
Marksans Pharma Ltd
IND

Company Assessment

(Last updated Apr 2025)
Marksans Pharma Ltd
Criticism
High ESG Risk
Sustainalytics, a top ESG research firm, evaluates environmental, social, and governance risks for over 16,000 companies. Its ESG Risk Rating reflects how much risk a company faces in its industry and how well it manages those risks. The final score includes both unmanaged and unmanageable risks, and companies are rated on a scale from negligible (0-10) to severe (40+). This company received an ESG Risk Rating of 38.2, placing it in the "high risk" category (retrieved April 2025).
> About the Icons

Company Details

Subsidiaries:
Nova Pharmaceuticals Australasia Pty Ltd (60% owned)
Pharmaceuticals
Founded in 2003 in Sydney Australia. New Zealand subsidiary set up in 2005. Largest supplier of generic & private label products in Australasia. Acquired by Marksans Pharma in 2005.

Contact Details

Address:
Mumbai, India
Website:
www.marksanspharma.com

Products / Brands

Nova Pharmaceuticals (60% owned)
Medix Medicinal Oils